NEW YORK, June 30, 2015 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired American Depositary Receipts of QRx Pharma, Ltd. ("QRx Pharma") (OTCMKTS:QRXPY) (OTCMKTS:QRXPF) between January 24, 2011 and April 23, 2014.
You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Southern District of New York. If you purchased or otherwise acquired QRx Pharma ADRs between January 24, 2011 and April 23, 2014, your rights may be affected by this action. To get more information go to:
http://zlk.9nl.com/qrx-pharma-qrxpy
or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that the Company made false and/or misleading statements and/or omitted material information concerning the commercial prospects for its experimental drug Moxduo. Among other allegations, the complaint alleges that the Company failed to disclose that it received a "no agreement letter" from the FDA regarding its trials for Moxduo.
If you suffered a loss in QRx Pharma you have until August 24, 2015 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.